Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.
Euro Surveill
; 26(26)2021 07.
Article
in English
| MEDLINE | ID: covidwho-1295603
ABSTRACT
Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Humans
/
Young adult
Country/Region as subject:
Europa
Language:
English
Journal subject:
Communicable Diseases
Year:
2021
Document Type:
Article
Affiliation country:
1560-7917.ES.2021.26.26.2100533
Similar
MEDLINE
...
LILACS
LIS